SCHEMBL1746687

SCHEMBL1746687

CCc1cccc(CC)c1-c1cccc(C=O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.51
TRIM24 O15164 1/20 0.45
TRIM33 Q9UPN9 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
ALDH1A1 P00352 2/20 0.42
UNG P13051 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
CDK8 P49336 1/20 0.38
DYRK1A Q13627 3/20 0.38
DYRK2 Q92630 3/20 0.38
DYRK1B Q9Y463 3/20 0.38
GABRA1 P14867 2/20 0.38
GABRB2 P47870 2/20 0.38
DYRK3 O43781 2/20 0.38
CCNT1 O60563 2/20 0.38
CDK9 P50750 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203685 0.86 BRD4 (0.47) BRD4TRIM24TRIM33CA12CA1
SCHEMBL6423019 0.82 TRPA1 (0.43) BRD4TRIM24TRIM33CA12CA1
SCHEMBL3815155 0.78 BCL2 (0.51) BRD4TRIM24TRIM33CA12CA1
SCHEMBL346974 0.77 TRIM24 (0.64) BRD4TRIM24TRIM33CA12CA1
SCHEMBL1745297 0.77 BRD4 (0.58) BRD4TRIM24TRIM33CA12CA1
SCHEMBL5735233 0.76 TRIM24 (0.56) BRD4TRIM24TRIM33CA12CA1
SCHEMBL27621710 0.75 TRIM24 (0.68) BRD4TRIM24TRIM33CA12CA1
SCHEMBL12578052 0.75 RAB9A (0.53) ALDH1A1NPC1RAB9AMAOAMAOB
SCHEMBL9914787 0.75 BRD4 (0.51) BRD4TRIM24TRIM33CA12CA1
SCHEMBL1974835 0.74 BRD4 (0.55) BRD4TRIM24TRIM33CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-2011788-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2009-01-07 EP disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186909-A1 Oxadiazolidinedione Compound GPR119, GPR39, GPR65 BRD4 273/4885TRIM24 911/4885TRIM33 1246/4885
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR BRD4 1593/4885TRIM24 853/4885TRIM33 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.